In a first renal outcome trial of its kind, the SGLT2 inhibitor showed favorable outcomes in the most advanced stages of CKD.

Compass Pathways' latest update reveals extended trial timelines, staff cuts, and financial concerns, raising questions about ...

Shuttle Pharmaceuticals (NASDAQ: SHPH), a rising force in cancer treatment innovation, has experienced a notable boost in its ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Long-term treatment with the cell therapy NurOwn was found to significantly extend survival for ALS patients compared with ...

The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.

Bright Minds Biosciences' BMB-101 shows promise in treating drug-resistant epilepsy. Read why DRUG stock is a strong ...

ESSA Pharma has terminated the Phase II clinical trial of masofaniten, a new prostate cancer treatment. Masofaniten, previously known as EPI-7386, is an investigational oral, small-molecule androgen ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment SEOUL, ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

PAR made substantial progress in its Phase 3 clinical trial preparations for the treatment of knee osteoarthritis (OA) with ...